@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAtv9BcZse838vIfylSguOwAsElAAdajRZ_q5foXCc6BQ> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAtv9BcZse838vIfylSguOwAsElAAdajRZ_q5foXCc6BQ#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix schem: <http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-chemicals/> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 hasAgent: sub:_2 ;
    a go:0003824 .
  sub:_2 geneProductOf: hgnc:5464 ;
    a Protein: .
  sub:_3 occursIn: do:162 , obo:UBERON_0000310 , species:9606 ;
    rdf:object sub:_1 ;
    rdf:predicate belv:decreases ;
    rdf:subject schem:Tretinoin ;
    a rdf:Statement .
  sub:assertion rdfs:label "a(SCHEM:Tretinoin) -| cat(p(HGNC:IGF1))" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "20131211" .
  sub:_4 prov:value "IGFbPs limit IGF access to IGF1R, thereby attenuating the bioactivity of these growth factors33. The tumour suppressor p53 (REF. 34), as well as many growth inhibitors including vitamin d35, anti- oestrogens36, retinoids37, and transforming growth factor-? (TGF?37), reduce IGF bioactivity by increasing the secretion of IGFbPs33." ;
    prov:wasQuotedFrom pubmed:19029956 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:19029956 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:33:29.444+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}